RA Capital Management’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
|
|||||
|
2025
Q2 | $17M | Hold |
|
|||||
|
2025
Q1 | $16.7M | Hold |
|
|||||
|
2024
Q4 | $19.1M | Sell |
|
|||||
|
2024
Q3 | $27.1M | Sell |
|
|||||
|
2024
Q2 | $49.6M | Hold |
|
|||||
|
2024
Q1 | $37.3M | Hold |
|
|||||
|
2023
Q4 | $29.4M | Hold |
|
|||||
|
2023
Q3 | $29M | Hold |
|
|||||
|
2023
Q2 | $43.3M | Hold |
|
|||||
|
2023
Q1 | $46.5M | Buy |
|
|||||
|
2022
Q4 | $13.3M | Buy |
|
|||||
|
2021
Q3 | – | Sell |
|
|||||
|
2021
Q2 | $1.97M | Hold |
|
|||||
|
2021
Q1 | $2.1M | Hold |
|
|||||
|
2020
Q4 | $5.49M | Sell |
|
|||||
|
2020
Q3 | $5.08M | Sell |
|
|||||
|
2020
Q2 | $22.9M | Sell |
|
|||||
|
2020
Q1 | $23.3M | Buy |
|